openPR Logo
Press release

Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028

12-05-2018 05:01 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fact.MR

/ PR Agency: Fact.MR
Pegfilgrastim Biosimilar Market: Industry Trends

Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by chemotherapy, HIV/AIDS, radiation poisoning or some other unknown source. It stimulates the growth of white blood cells which are used to fight infections in the body. Pegfilgrastim biosimilar is an existing medical product that fights low white blood cell levels. The Pegfilgrastim biosimilar market is an expanding market in the US. Pegfilgrastim biosimilar is the long-acting drug form of Filgrastim. It has a human half-life of approximately 15-80 hours, which is more than the parent Filgrastim. Pegfilgrastim biosimilar named Fulphila (Pegfilgrastim-jmdb), produced by Biocon/Mylan, collaboration has recently been approved by the US FDA as the first Biosimilar to Neulasta, which is an existing medical product used to treat low blood neutrophils levels. Pegfilgrastim Biosimilar is almost identical to Neulasta, which was the first drug used to fight low neutrophils levels.

Increasing prevalence of diseases, such as cancer and HIV/AIDS, will drive the growth of the Pegfilgrastim Biosimilar market. Pegfilgrastim biosimilar also fights infections and controls low blood neutrophils level in patients having undergone chemotherapy, radiation poisoning, etc. Pegfilgrastim Biosimilar is cheaper than Pegfilgrastim, which might also contribute to the expansion of the Pegfilgrastim Biosimilar market over the forecast period. However, side effects related to Pegfilgrastim Biosimilar, such as bone pain, acute respiratory distress syndrome, rupture of the spleen and other allergic reactions, might hinder the growth of Pegfilgrastim Biosimilar market. Reimbursement policies for Biosimilar in the market are also not well appreciated and could restrain the growth of Pegfilgrastim Biosimilar market over the forecast period.

Increasing incidences of cancer are leading to increased chemotherapy procedures. Myelosuppressive or Induction chemotherapy is anticipated to grow significantly due to growing pool of cancer patients. Pegfilgrastim stimulates the growth of healthy WBCs in the bone marrow, which helps fight any infection occurring post the chemotherapy procedure. The patients are heavily exposed to radiations which are poisonous and can damage the bone marrow. Therefore, the use of Pegfilgrastim Biosimilar in bone marrow transplantation is also anticipated to increase during the forecast period. Based on the distribution channels, hospital pharmacies will witness fastest growth in the Pegfilgrastim Biosimilar market.

North America’s Pegfilgrastim Biosimilar market is anticipated to grow at a rapid pace over the forecast period due to growing incidences of cancer, increase in health expenditure and easy affordability because of cost cuts. The Australia and New Zealand Pegfilgrastim Biosimilar market is anticipated to grow significantly owing to growth in the cases of acute chronic neutropenia, cancer and HIV/AIDS. Europe’s Pegfilgrastim Biosimilar market is expected to grow at a moderate rate over the forecast period owing to poor research and development investments by local governments, less GDP per capita and varying regulatory and competitive dynamics in different countries.

Get Experts' Insights For FREE: https://www.factmr.com/connectus/sample?flag=S&rep_id=1494

The first Pegfilgrastim Biosimilar product named Fulphila (Pegfilgrastim-jmdb) by Mylan-Biocon collaboration has been approved by US FDA and will soon be launched in the market. Other companies that have filed applications for Pegfilgrastim Biosimilar include USV Biologics, Cinfa Biotech, Coherus, Sandoz, Stada Arzneimittel/Gedeon Richter and Pfizer.

Report Overview at https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028 here

News-ID: 1419761 • Views:

More Releases from Fact.MR

Fine Blanking Tools Market Projected to Reach USD 1.43 Billion by 2035 | U.S. CAGR at a 5.3%
Fine Blanking Tools Market Projected to Reach USD 1.43 Billion by 2035 | U.S. CA …
The global Fine Blanking Tools Market is set for steady growth over the next decade, driven by rising demand for high-precision components, ongoing industrial automation, and surging requirements from automotive, electronics, and aerospace sectors. According to a recent forecast, the market is expected to grow from approximately USD 948.1 million in 2025 to USD 1,430.6 million by 2035, at a compound annual growth rate (CAGR) of about 4.2 % between
Benzodiazepine Drugs Market is Expanding USD 5.4 billion by 2035 | Pfizer Inc.; Akorn Inc; Hikma; Hameln Pharmaceutical; Accord; Others.
10-08-2025 | Health & Medicine
Fact.MR
Benzodiazepine Drugs Market is Expanding USD 5.4 billion by 2035 | Pfizer Inc.; …
The global benzodiazepine drugs market is projected to expand in the coming decade, driven by growing incidence of anxiety, insomnia, alcohol-withdrawal disorders, and advances in pharmaceutical formulations. According to a recent Fact.MR report, the market was valued at approximately USD 2.35 billion in 2022, and is expected to grow at a compound annual growth rate (CAGR) of 2.8% to reach USD 3.1 billion by 2032. Market Drivers & Outlook The demand for
Ultrasound Systems Market to Surge to Nearly USD 20 Billion by 2035, Led by Advances in 2D, Cart-Based Systems & AI-Enabled Portability
10-08-2025 | Health & Medicine
Fact.MR
Ultrasound Systems Market to Surge to Nearly USD 20 Billion by 2035, Led by Adva …
The global Ultrasound Systems Market is on a strong growth trajectory, projected to rise from USD 10.8 billion in 2025 to approximately USD 19.7 billion by 2035, expanding at a CAGR of 6.2% during the forecast period. This growth is fueled by the rising demand for non-invasive diagnostic imaging, the increasing prevalence of chronic diseases, expanding healthcare infrastructure, and continuous technological innovations such as AI integration and portable imaging systems. Key
Surgical Staplers Market Is Forecasted To Reach USD 6.0 Billion In 2025 | Ethicon US LLC, Cardica Inc., Smith & Nephew Plc, CONMED Corporation., Purple Surgical Inc., Dextera Surgical Inc, and Others.
10-08-2025 | Health & Medicine
Fact.MR
Surgical Staplers Market Is Forecasted To Reach USD 6.0 Billion In 2025 | Ethico …
The global Surgical Staplers Market is forecast to show strong growth over the next decade, nearly doubling in value as demand surges for efficient, reliable wound closure in advanced surgical procedures. According to the latest Fact.MR Surgical Staplers Market Size & Share Forecast Outlook 2025-2035 report, the market is expected to grow from USD 6.0 billion in 2025 to USD 12.5 billion by 2035, at a compound annual growth rate

All 5 Releases


More Releases for Pegfilgrastim

Pegfilgrastim Biosimilar Market: Emerging Trends and Growth Forecast to 2033
The global Pegfilgrastim Biosimilar Market, valued at approximately USD 1.56 billion in 2024, is projected to reach around USD 6.36 billion by 2033, growing at a CAGR of 17.1% from 2025 to 2033. Pegfilgrastim Biosimilar Market Overview The Pegfilgrastim Biosimilars Market is experiencing rapid growth due to the increasing prevalence of cancer and the rising demand for cost-effective treatment alternatives to branded biologics. Pegfilgrastim, used to prevent neutropenia in cancer patients undergoing
Global Neulasta (Pegfilgrastim) And Biosimilar Market Size by Application, Type, …
USA, New Jersey- According to Market Research Intellect, the global Neulasta (Pegfilgrastim) And Biosimilar market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period. The market for pegfilgrastim and biosimilars is expanding significantly, mostly due to the rising use of chemotherapy-based cancer treatments. By promoting the formation
Global Pegfilgrastim Market Expects 5.8% Growth Rate from 2021-2028 Amid Rising …
According to the latest report published by Dataintelo, the Global Pegfilgrastim Market is projected to expand at a compound annual growth rate (𝐂𝐀𝐆𝐑) of 5.8% during the period between 2021 and 2028. This significant expansion in the market is primarily driven by the escalating number of cancer cases worldwide and an intensified demand for pegfilgrastim biosimilars. The report highlights that the evolving global scenario of cancer management and treatment is fostering
05-04-2021 | Health & Medicine
Fact.MR
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia. Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market Neutropenia patients are highly
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts. Pegfilgrastim is a PEGylated
Pegfilgrastim Industry Business Outlook and Procurement Survey To 2017
Market Reports Center has released its latest research-based report entitled ‘Pegfilgrastim market.' This comprehensive report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Pegfilgrastim market worldwide along with the key trends and latest technologies, playing a prominent role in the Pegfilgrastim market growth over the predicted period. It also takes into account the market trends, aspects like